The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Visual abstract | Efficacy and safety of midostaurin plus intensive chemotherapy in newly diagnosed patients with FLT3-mutated AML
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Question 1 of 1
In the study by Sierra et al. there was no difference observed in the frequency of adverse events between the age groups (≤60 and ≥60 years). However, which of the following adverse events was numerically higher in the older patients (aged ≥60 years)?
A
B
C
D
FMS-like tyrosine kinase 3 (FLT3) is a commonly occurring gene mutation in approximately 30% of patients with acute myeloid leukemia (AML). Midostaurin is a multikinase, first-generation, type 2 inhibitor that directly inhibits FLT3 signaling and induces apoptosis in FLT3-mutated leukemic cells. The pivotal RATIFY trial, previously reported by the AML Hub, demonstrated that midostaurin significantly reduced mortality in adult patients aged <60 years with newly diagnosed FLT3-mutated AML.1
The AML Hub is pleased to present a visual abstract summarizing the efficacy and safety outcomes from a phase IIIb trial (NCT03379727) of midostaurin plus idarubicin or daunorubicin in young (≤60 years) and older (≥60 years) patients with newly diagnosed FLT3-mutated AML.1
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Approximately what proportion of your patients with FLT3-mutations also have NPM1 and DNMT3A co-mutations?